Search
News & Events
Extra whooping cough shots to protect bubsAn extra whooping cough vaccination for babies comes as a result of work by researchers at the Wesfarmers Centre of Vaccines and Infectious Diseases.
News & Events
Free vaccination public seminarImmunisation plays an important role in preventing disease within our community. Join us at a FREE public seminar on vaccinations.
News & Events
Trans Tasman action to fast track rheumatic fever vaccinePrime Ministers of Australia and New Zealand have agreed to provide $3M to help fast-track the development of a vaccine against rheumatic fever.
News & Events
State Immunisation Strategy ReleasedThe State Government has launched a new strategy for improving immunisation rates among WA children, to prevent outbreaks of diseases like measles & meningitis
News & Events
New study examines vacccine to prevent cervical cancerThe Telethon Institute for Child Health Research today announced a new study investigating a vaccine to prevent infection of Human Papilloma Virus (HPV).
Research
Paediatric Active Enhanced Diseases Surveillance (PAEDS)PAEDS monitors for key vaccine preventable conditions and severe side effects from vaccine in 5 paediatric hospitals in Australia.
Research
Whooping CoughWhooping cough (pertussis) is a highly contagious respiratory infection which causes a severe cough and can be particularly dangerous to babies under a year old. Vaccination is the best way to reduce the risk of whooping cough.
Research
Evaluation of Pediatric HIV Postexposure Prophylaxis Guideline Following Child Sexual Assault in Western AustraliaHIV postexposure prophylaxis (PEP) following child sexual assault (CSA) is recommended in select cases. High rates of poor adherence to PEP are reported. We evaluated adherence to the recommended management of children following CSA at the tertiary pediatric facility in Western Australia and compared our approach with international guidelines.
Research
Short term safety profile of respiratory syncytial virus vaccine in adults aged ≥ 60 years in AustraliaAustralia's active vaccine safety surveillance system AusVaxSafety monitors a number of vaccines, including Arexvy, by reporting on solicited adverse events following immunisation (AEFI) through an online survey sent to vaccinees 3 days post-vaccination as previously described.3 Here we report on survey responses from adults aged ≥60 years receiving Arexvy at primary healthcare practices or pharmacies, who responded to the survey by day 7 post-vaccination.
Research
Safety and Immunogenicity of Neonatal Pneumococcal Conjugate Vaccination in Papua New Guinean Children: A Randomised Controlled TrialWe conducted an open randomized controlled trial in Papua New Guinea to compare safety, immunogenicity and priming for memory of 7-valent PCV (PCV7) given in...